Iniparib - Sanofi

Drug Profile

Iniparib - Sanofi

Alternative Names: BSI-201; SAR-240550

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BiPar Sciences
  • Developer BiPar Sciences; National Cancer Institute (USA); Sanofi
  • Class Antineoplastics; Benzamides; Iodobenzenes; Nitro compounds; Small molecules
  • Mechanism of Action Cell cycle inhibitors; H2AFX protein stimulants; Tumour protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain metastases; Breast cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Feb 2017 Sanofi completes the phase II SOLTI NEOPARP trial in Breast cancer (Combination therapy, Neoadjuvant therapy) in France, Germany and Spain (IV, Infusion) (NCT01204125)
  • 01 Jun 2015 Sanofi completes a phase I/II trial in Glioblastoma in USA (NCT00687765)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top